June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function
Author Affiliations & Notes
  • Maria Lucia Cascavilla
    Scientific Inst San Raffaele, Segrate-Mi2, Italy
  • Giuseppe Querques
    Scientific Inst San Raffaele, Segrate-Mi2, Italy
    University Paris-Est Creteil, Parigi, France
  • Rosangela Lattanzio
    Scientific Inst San Raffaele, Segrate-Mi2, Italy
  • Lea Querques
    Scientific Inst San Raffaele, Segrate-Mi2, Italy
  • Giacinto Triolo
    Scientific Inst San Raffaele, Segrate-Mi2, Italy
  • Edoardo Cavallero
    Scientific Inst San Raffaele, Segrate-Mi2, Italy
  • Francesco Bandello
    Scientific Inst San Raffaele, Segrate-Mi2, Italy
  • Footnotes
    Commercial Relationships Maria Lucia Cascavilla, None; Giuseppe Querques, None; Rosangela Lattanzio, None; Lea Querques, None; Giacinto Triolo, None; Edoardo Cavallero, None; Francesco Bandello, ALLERGAN Inc. (S), NOVARTIS PHARMACEUTICALS CORPORATION (S), FARMILA-THEA (S), BAYER SCHERING PHARMA (S), PFIZER Inc. (S), ALCON Inc. (S), BAUSCH AND LOMB (S), GENENTECH Inc. (S), ALIMERA SCIENCES Inc. (S), SANOFI AVENTIS (S), THROMBOGENICS (S)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1958. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maria Lucia Cascavilla, Giuseppe Querques, Rosangela Lattanzio, Lea Querques, Giacinto Triolo, Edoardo Cavallero, Francesco Bandello; Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1958.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate changes in macular sensitivity after intravitreal dexamethasone implant for macular edema (ME) secondary to retinal vein occlusion (RVO)

Methods: 19 treatment-naive patients with decreased visual acuity due to RVO-related ME were enrolled in this prospective uncontrolled study.Patients were treated with intravitreal Ozurdex (and retreated on as needed basis), and followed up at 1 month 3,4,5 and 6 mos for the evaluation of morphological and functional outcomes, by means of BCVA,microperimetry (MP), and spectral-domain OCT

Results: 19 eyes (13 central [C]RVO eyes,6 branch [B]RVO eyes)of 19 patients were included for analysis.At 1 month (19 eyes)mean BCVA,retinal sensitivity,and central macular thickness (CMT) improved from 0.50±0.34 LogMAR, 10.51±4.31 dB, and 762±259 μm to 0.38±0.34 LogMAR, 12.28±5.06 dB, and 385±191 μm,respectively.At 3 months (19 eyes) improvement of mean BCVA,retinal sensitivity,and CMT decreased (0.54±0.36 LogMAR,11.62±5.05 dB, and 518±251 μm);at this time point, 2 eyes were retreated with intravitreal dexamethasone.At 4 months (17 eyes)mean BCVA,retinal sensitivity and CMT were 0.68±0.45 LogMAR,8.64±4.45dB, and 671±239 μm respectively;at this time point, 4 eyes were retreated.At 5 months (13 eyes) mean BCVA, retinal sensitivity, and CMT were 0.83 ±0.42 LogMAR, 8.1±3.4 dB, and 670±218 μm ;at this time point, 6 eyes were retreated. Interestingly 7 eyes (4 eyes with CRVO, 3 eyes with BRVO)did not underwent retreatment up to 6 months from first intravitreal dexamethasone;in these eyes mean BCVA,retinal sensitivity,and CMT changed from 0.46±0.29 LogMAR, 12.27±3.52 dB, and 715±219 μm (baseline, versus 0.53±0.37LogMAR, 9.48±4.53dB, and 790±286μm, in eyes that underwent retreatment <6 months),to 0.41±0.45 LogMAR, 11.33±5.32 dB, and 547±216 μm (6 months).At 6 months, 5 eyes were retreated. 1 month after retreatment with intravitreal dexamethasone (12 eyes) mean BCVA, retinal sensitivity, and CMT improved from last pre-retreatment visit (from 0.93±0.77 LogMAR,8.42±3.98 dB, and 711±172 μm to 0.77±0.46LogMAR [p=0.03], 10.63 ±4.63 dB [p=0.04], and 497±262 μm [p=0.01])

Conclusions: In eyes with ME secondary to RVO, MP shows improvement in macular sensitivity 1 month after treatment/retreatment with intravitreal dexamethasone.Eyes that underwent retreatment <6 months showed a worse baseline BCVA,and macular sensitivity compared with eyes not requiring retreatment up to 6 months

Keywords: 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×